Mazdutide vs Retatrutide: How Do These Two Next-Gen Peptides Compare?
Quick Answer
Mazdutide is a dual GLP-1/glucagon receptor agonist, while retatrutide adds GIP receptor activation to become a triple agonist. Both peptides target metabolic pathways tied to appetite regulation, fat breakdown, and energy expenditure, but retatrutide's third receptor may drive larger effects based on current trial data. Researchers looking beyond single-target compounds often weigh these two against each other.
What Is Mazdutide?
Mazdutide (also called IBI362) is a once-weekly injectable peptide developed by Innovent Biologics. It acts on two receptors:
- GLP-1 (glucagon-like peptide-1): slows gastric emptying and reduces appetite signaling
- Glucagon receptor: raises energy expenditure and promotes fat breakdown (lipolysis)
The dual-agonist design aims to capture appetite reduction through GLP-1 while using glucagon to increase metabolic rate. Some researchers find this combination relevant for studying fat loss pathways without relying on a single mechanism.
In clinical studies, mazdutide has been investigated at doses ranging from 3 mg to 9 mg administered subcutaneously once weekly . Phase 2 data from the IBI362 program showed meaningful reductions in body weight and improvements in metabolic markers . Phase 3 trials are ongoing as of 2026.
Evidence level: Phase 2 and Phase 3 trial data available; not approved for general use outside of approved trials.
What Is Retatrutide?
Retatrutide (LY3437943) is a once-weekly injectable peptide developed by Eli Lilly. It is sometimes called a "triple G" agonist because it activates three distinct receptors:
- GLP-1: appetite suppression and slowed gastric emptying
- GIP (glucose-dependent insulinotropic polypeptide): modulates insulin release and fat storage signaling
- Glucagon receptor: thermogenesis and lipolysis
The triple mechanism is retatrutide's defining feature. In a Phase 2 trial published in the New England Journal of Medicine , participants receiving the highest dose of 12 mg weekly achieved approximately 24% mean body weight reduction over 48 weeks . That result drew substantial research interest because it exceeded what earlier dual agonists had shown in comparable timeframes.
Research doses studied in clinical trials range from 1 mg to 12 mg subcutaneously once weekly . Dose-escalation schedules in those trials typically ran over several weeks to manage tolerability .
Evidence level: Phase 2 data published in a peer-reviewed journal; Phase 3 trials underway; not FDA-approved for general use.
Comparison at a Glance
| Feature | Mazdutide | Retatrutide |
|---|---|---|
| Type/Form | Dual agonist (GLP-1 + glucagon), injectable | Triple agonist (GLP-1 + GIP + glucagon), injectable |
| Mechanism | Appetite reduction + thermogenesis via two pathways | Appetite reduction + insulin modulation + thermogenesis via three pathways |
| Typical research dose | 3 mg to 9 mg subcutaneous weekly | 1 mg to 12 mg subcutaneous weekly |
| Evidence level | Phase 2/3 trials; not approved for general use | Phase 2 published; Phase 3 ongoing; not approved for general use |
Key Differences
1. Number of receptor targets
The most direct difference is how many receptors each compound activates. Mazdutide hits two; retatrutide hits three. Adding GIP to the mix changes how the body handles fat storage and insulin dynamics in ways the dual-agonist pathway does not replicate. This third receptor is not just a bonus layer. It interacts with GLP-1 signaling in ways researchers are still characterizing.
2. Magnitude of weight-related changes in published data
Available Phase 2 data suggest retatrutide's triple mechanism produces larger average body weight changes. The approximately 24% reduction figure from Lilly's Phase 2 publication has not been matched in head-to-head comparisons with dual agonists. Mazdutide's Phase 2 data show significant but comparatively lower reductions . No direct head-to-head trial has been published between these two.
3. Developer and trial infrastructure
Retatrutide comes from Eli Lilly, a large pharmaceutical company with broad international trial networks. Mazdutide is developed by Innovent Biologics, a Chinese biopharmaceutical company. Both are running late-stage development programs, but Lilly's global reach means retatrutide's published data covers more diverse study populations.
4. GIP receptor component and research tracking
The GIP addition in retatrutide is the most mechanistically interesting variable for researchers familiar with tirzepatide, which also targets GIP. Tracking how each compound affects body weight, energy, and tolerability across a full research protocol requires careful logging. Researchers using DoseVault can document dose timings, side effect patterns, and protocol notes in a structured way that makes comparing compound responses easier over time.
Can You Stack Them?
Stacking mazdutide and retatrutide would mean combining two compounds that both activate the GLP-1 receptor, plus overlapping glucagon receptor stimulation. This creates additive receptor loading on shared pathways without clear evidence of proportional benefit. The risk of nausea, vomiting, and other GLP-1-class side effects would be additive at minimum.
There is no published human data on this combination . The degree of receptor overlap makes a clean rationale for stacking difficult to support.
Before considering any protocol involving either compound individually, consult a licensed clinician. These are investigational peptides with real side effect profiles. Dosing decisions require professional supervision and ideally baseline lab work.
Frequently Asked Questions
What is the main difference between mazdutide and retatrutide?
Mazdutide targets GLP-1 and glucagon receptors (dual agonist), while retatrutide adds GIP receptor activation to become a triple agonist. The extra pathway may account for retatrutide's larger weight changes seen in Phase 2 data.
What weight loss results has retatrutide shown in clinical trials?
In a published Phase 2 trial, participants on the highest 12 mg weekly dose saw approximately 24% mean body weight reduction over 48 weeks . Results vary by dose and individual response.
Is mazdutide the same as a GLP-1 agonist like semaglutide?
No. Mazdutide adds glucagon receptor activation on top of GLP-1 signaling, which targets thermogenesis and fat breakdown more directly than GLP-1 alone. It is not the same as semaglutide.
Are mazdutide and retatrutide FDA-approved?
Neither compound is FDA-approved for general use as of 2026 . Both are in active clinical development. Access outside of approved clinical trials is not sanctioned by regulatory agencies.
Who Picks Each, and When?
Researchers gravitating toward mazdutide:
- Interested in studying the GLP-1/glucagon dual mechanism in isolation, without the GIP variable
- Want to follow Innovent Biologics' trial program specifically
- Researching the thermogenesis and lipolysis angle driven by glucagon in a more controlled form
Researchers gravitating toward retatrutide:
- Want the broadest published trial data on a triple agonist, including a high-profile New England Journal of Medicine publication
- Interested in how GIP receptor activation interacts with weight loss and fat storage
- Following Eli Lilly's pipeline and Phase 3 endpoints closely
Neither compound is a casual research choice. Both require careful protocol design, baseline lab work, dose-escalation awareness, and ongoing monitoring.
Related
- Retatrutide
- Can You Microdose Retatrutide?
- Does Retatrutide Cause Nausea?
- How Long Does Retatrutide Take to Work?
- How to Reconstitute Retatrutide
- Peptides for Fat Loss
Disclaimer: This page is for educational purposes only and does not constitute medical advice. Mazdutide and retatrutide are not FDA-approved for general use. Do not use these compounds without guidance from a licensed healthcare provider.
Built by medical professionals, gym rats, and experienced biohackers
Tracking your peptide research properly matters. DoseVault is built for researchers who want to log compounds, record dose timings, and monitor how protocols evolve over time. Start organizing your research at https://dosevault.app.